The authors claim that the substance found will help effectively fight most infectious diseases of humans and animals caused by bacteria and fungi.
According to University scientists, one of the tasks of pharmacology is to find natural antibiotics that can fight against microorganisms that have multiple (multi-drug resistant, MDR) or absolute (extreme-drug resistant, XDR) resistance to antibiotics available on the market. Researchers from TSU were the first in the world to demonstrate the unique ability of the emericillipsin a peptide isolated from the alkalophilic mycellial fungus Emericellopsis alkalina. According to experts, the substance suppresses the ability of bacteria to form biofilms, so that the resistance of these pathogens to antibiotics disappears.
As the authors explained, the main therapeutic feature of the studied substance is the universality of the effect. Not only MDR and XDR forms of bacteria are vulnerable to emericillipsin A, but also almost any pathogenic eukaryotes — such as mycellial fungi and yeast. "Amaryllises And acting on eukaryotes and prokaryotes, due to different molecular mechanisms. Eukaryotes-fungi and tumor cells-die due to the destruction of their cell membrane by the peptide, and the virulence of prokaryotes is suppressed by preventing the formation of biofilms," said Evgeny Rogozhin, senior researcher at the x — BIO antimicrobial resistance laboratory at TSU. As noted by scholars, among the pathologies with which will allow you to fight amaryllises And tumors, as well as various bacterial and fungal infections.
According to TSU specialists, emericillipsin A is promising both as an independent treatment and as an element of complex medications. Therapy can be carried out either through injections, or locally — by direct treatment of the affected tissues.
The study was conducted in close cooperation with colleagues from research Institute to find new antibiotics them. G. F. gauze, Central research Institute of epidemiology and Institute of Bioorganic chemistry. M. M. Shemyakin and Y. A. Ovchinnikov Russian Academy of Sciences.
In the future, the team of scientists intends to switch from working with cell models to laboratory tests of the drug.